Platelet aggregation inhibitors

Platelet aggregation inhibitors

Clopidogrel and prasugrel selectively inhibit the ADP-receptor on the platelet. This inhibits platelet activation and subsequently aggregation by ADP (adenosinediphosphate). Clopidogrel and prasugrel are indicated in case of unstable angina, after coronary angioplasty and after coronary stenting. It can also be used in case of aspirin intolerance. It is at least as effective and possibly more effective than aspirin (see further). The major adverse effects involve gastrointestinal problems and bleeding.

Clodipogrel is much more

expensive than aspirin. However, recent studies (CURE and CLARITY) have shown the benefit of adding clopidogrel to aspirin rather than using aspirin alone in patients having acute coronary syndromes without ST-segment elevation myocardial infarction.

Abciximab is a monoclonal antibody that binds to the GPIIb/IIIa complex and thereby inhibits the binding of activated platelets to fibrinogen and VWF.

For information on aspirin check aspirin.

See also platelet aggregation inhibitors

1

Clopidogrel inhibits platelet aggregation for